Striking two targets with one scaffold via benzo[d]imidazole-isatin conjugates as potent dual VEGFR-2/c-MET antagonists
Bioorganic & Medicinal Chemistry · 2026
DOI: 10.1016/j.bmc.2026.118784 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry, 2026. Verfasst von Mohamed El-Naggar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Biotechnology Center, Research Institute for Sciences and Engineering, University of Sharjah, 27272, the United Arab Emirates; Department of…. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-met, Antineoplastic Agents. Die Arbeit nennt 59 Literaturangaben.
Abstract (Originalsprache)
A series of benzo[d]imidazole-isatin hybrids (4a-d, 6a-d, and 8a-d) was developed and synthesized as prospective dual inhibitors of VEGFR-2 and c-MET to address tumor growth and resistance-related signaling pathways. The biological assessment demonstrated encouraging dual kinase inhibitory action, with compound 8b identified as the most balanced inhibitor, displaying IC50 values of 92 nM and 63 nM against VEGFR-2 and c-MET, respectively. In-vitro antiproliferative evaluation against MDA-MB-231 and A549 cancer cell lines revealed notable cytotoxicity for compound 8b, yielding IC50 values of 2.37 μM and 1.79 μM, respectively, exceeding the efficacy of the reference medication sunitinib. Additionally, 8b exhibited a favorable selectivity profile for normal MCF-10A cells. Mechanistic studies demonstrated that 8b caused substantial G2/M cell cycle arrest and facilitated apoptosis in MDA-MB-231 cells. Biomarker studies revealed a reduction in VEGF-A, MMP-9, and Bcl-2 levels, alongside an increase in Bax and Caspase-3, suggesting potential anti-angiogenic and pro-apoptotic characteristics in-vitro. Molecular docking analyses provided supporting models for the identified biological activities and exhibited advantageous binding interactions within both kinase active sites. These data collectively suggest that chemical 8b may serve as a promising candidate for further anticancer research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Advanced Biotechnology Center, Research Institute for Sciences and Engineering, University of Sharjah, 27272, the United Arab Emirates; Department of Chemistry, College of Sciences, University of Sharjah, 27272, the Uni…
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh, University, P.O. Box 33516, Kafrelsheikh, Egypt.
- Students' Hospital, Mansoura University, Mansoura, Egypt.
- Applied Organic Chemistry Department, National Research Center, Dokki, Cairo 12622, Egypt. Electronic address: hatem_741@yahoo.com.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alsalam University, 31511 Tanta, Egypt. Electronic address: mahmoudelkotami@gmail.com.
Zitieren
APA
El-Naggar, M., Salem, R., Kabeel, M. M., Shehadi, I. A., Eldehna, W. M., Abdel-Aziz, H. A., & Elkotamy, M. S. (2026). Striking two targets with one scaffold via benzo[d]imidazole-isatin conjugates as potent dual VEGFR-2/c-MET antagonists. Bioorganic & Medicinal Chemistry. https://doi.org/10.1016/j.bmc.2026.118784
Vancouver
El-Naggar M, Salem R, Kabeel MM, Shehadi IA, Eldehna WM, Abdel-Aziz HA, et al. Striking two targets with one scaffold via benzo[d]imidazole-isatin conjugates as potent dual VEGFR-2/c-MET antagonists. Bioorganic & Medicinal Chemistry. 2026. doi:10.1016/j.bmc.2026.118784
BibTeX
@article{ElNaggar2026,
author = {El-Naggar, Mohamed and Salem, Rofaida and Kabeel, Mona M and Shehadi, Ihsan A and Eldehna, Wagdy M and Abdel-Aziz, Hatem A and Elkotamy, Mahmoud S},
title = {Striking two targets with one scaffold via benzo[d]imidazole-isatin conjugates as potent dual VEGFR-2/c-MET antagonists},
journal = {Bioorganic & Medicinal Chemistry},
year = {2026},
doi = {10.1016/j.bmc.2026.118784}
}
EUVIMED